Your session is about to expire
← Back to Search
Pharmacogenomic Modulator
Exercise for Statin Toxicity
N/A
Waitlist Available
Led By Daniel J Parente, MD PhD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adults (aged 35-65 years)
English-speaking
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights
Study Summary
This study is evaluating whether genetic variations in proteins that metabolize/transport statins may impact the relationship between statin use and lack of benefit from exercise.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Peak oxygen consumption (VO2max)
Secondary outcome measures
Resting heart rate
Resting systolic blood pressure
Weight
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
University of Kansas Medical CenterLead Sponsor
458 Previous Clinical Trials
169,067 Total Patients Enrolled
Daniel J Parente, MD PhDPrincipal InvestigatorUniversity of Kansas Medical Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger